SAB Biotherapeutics, Inc. (SABSW)

Compare

0.0368

+0.0048

+(15.00%)

At close: January 31 at 4:00:00 PM EST

SAB BIO to Participate in Upcoming Investor Conferences

MIAMI, Jan. 31, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing SAB-142, a human anti-thymocyte immunoglobulin (hIgG) that potentially delays the onset or progression of type 1 diabetes (T1D), today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim SMID Cap Biotech ConferenceDate: February 6, 2025Fir

GlobeNewswire yesterday

SABS
+0.92%
SABSW
+15.00%
SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support that SAB-142 is well-positioned for re-dosing in outpatient setting for type 1 diabetesResults will be presented in an R&D webinar event today at 8:00 am ET; registration details below MIAMI, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharm

GlobeNewswire 4 days ago

SABS
+0.92%
SABSW
+15.00%
3 Promising US Penny Stocks With At Least $20M Market Cap

Recent market activity has been marked by volatility, with concerns about China's advancements in artificial intelligence impacting major indices and leading to a sell-off in technology and semiconductor stocks. Despite these fluctuations, certain investment opportunities remain attractive, particularly among penny stocks—an area that continues to intrigue investors due to its potential for significant returns. Penny stocks, often representing smaller or newer companies, can offer unique...

Simply Wall St. 4 days ago

FORA

BRLT

SABS
+0.92%
SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM ESTMIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase

GlobeNewswire 9 days ago

SABS
+0.92%
SABSW
+15.00%
SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

As the United States stock market navigates a complex landscape of inflation data and interest rate adjustments, investors are exploring diverse opportunities across various sectors. The term 'penny stocks' may seem outdated, but these smaller or newer companies can still offer potential for growth when they possess strong financial fundamentals. In this article, we explore three U.S. penny stocks that stand out for their financial resilience and potential to deliver value to investors...

Simply Wall St. last month

SABS
+0.92%
SABSW
+15.00%
DDL
These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts

The year is winding down, but the bull markets are still charging ahead, getting a boost from improved sentiment after the presidential election. While the next few months will be a time of transition, a few things are likely. The Trump administration is expected to pursue a far looser regulatory policy than the outgoing Biden government. Plans for individual tax cuts are projected to drive consumer spending, while reductions in corporate taxes could deliver an immediate boost to earnings. While

TipRanks 2 months ago

GNLX

SABS
+0.92%
SABSW
+15.00%
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB Biotherapeutics ( NASDAQ:SABS ) Third Quarter 2024 Results Key Financial Results Net loss: US$10.3m (loss widened...

Simply Wall St. 2 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported fin

GlobeNewswire 2 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Chairman and CEO Samuel J. Reich will be speaking at an upcoming fireside chat at the 2024 Guggenheim Securities Healthcare Innovation Conference held November 11th – 13th, 2024 in Boston, M

GlobeNewswire 3 months ago

SABS
+0.92%
SABSW
+15.00%
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Simply Wall St. 4 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

MIAMI, Sept. 13, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that Chairman and CEO Samuel J. Reich will be participating in a fireside chat at the 2024 Cantor Global Healthcare Conference, September 17-19th, 2024. Fireside Chat: September 18th, 2024, at 8:00 am ETLocation:

GlobeNewswire 4 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB-142 has completed Phase 1 enrollment of all planned cohorts in healthy volunteers and is progressing to enroll patients with type 1 diabetes in the last cohort of the study. Target dose of SAB-142 2.5mg/kg completed with no observation of serum sickness. SAB-142 remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Sept. 09, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunother

GlobeNewswire 4 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

MIAMI, Sept. 04, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present at the European Association for the Study of Diabetes 60th Annual Meeting on September 9, 2024 in Madrid. SAB’s Executive Vice President and Chief Medical Officer Alexandra

GlobeNewswire 4 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

FDA provided clearance to SAB’s IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30,

GlobeNewswire 5 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced the founding of a clinical advisory board to provide expert insight and guidance to the Company in the clinical development of SAB-142, its leading therapeutic candidate. The ne

GlobeNewswire 5 months ago

SABS
+0.92%
SABSW
+15.00%
SAB BIO Appoints Lucy To as Chief Financial Officer

MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that Lucy To has been named Chief Financial Officer effective August 12, 2024. Ms. To brings over 18 years of investment banking and strategic operational expertise to SA

GlobeNewswire 5 months ago

SABS
+0.92%
SABSW
+15.00%
SAb Biotherapeutics Rebrands as SAB BIO

New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced its new name, SAB BIO

GlobeNewswire 7 months ago

SABS
+0.92%
SABSW
+15.00%
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst

GlobeNewswire 7 months ago

SABS
+0.92%
SABSW
+15.00%
SAB Biotherapeutics Announces Departure of Chief Financial Officer

MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of T1D, today announced that effective June 4, its Chief Financial Officer Michael King will be departing the company to accept a role as CEO at a privately-held oncology company. He will continue as an advisor to SAB through

GlobeNewswire 7 months ago

SABS
+0.92%
SABSW
+15.00%
FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics

This regulatory clearance enables clinical development of SAB-142 in patients with type 1 diabetes in the USMIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the Company’s investigational new drug (IND) application to proceed for its phase 1 clinical trial for type 1 diabetes (T1D) therapy SAB-142. SAB is a clinical-stage biopharmaceutical company with a

GlobeNewswire 8 months ago

SABS
+0.92%
SABSW
+15.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SAB Biotherapeutics, Inc. (SABSW)

SAB BIO to Participate in Upcoming Investor Conferences

SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142

3 Promising US Penny Stocks With At Least $20M Market Cap

SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy

SAB Biotherapeutics Leads The Pack Of 3 US Penny Stocks To Consider

These 2 “Strong Buy” Penny Stocks Are Set to Triple (or more), Say Analysts

SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023)

SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update

SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference

SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely

SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference

SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting

SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting

SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates

SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes

SAB BIO Appoints Lucy To as Chief Financial Officer

SAb Biotherapeutics Rebrands as SAB BIO

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

SAB Biotherapeutics Announces Departure of Chief Financial Officer

FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics